semaglutide cardiovascular risk Weight loss and disease outcomes of semaglutide: a one-year multicentered study 🚨 Breaking News: Real-World Data

Weight gain during perimenopause is a common concern, which is exacerbated by hormonal changes

Talk to your doctor to find out more about the side effects of GLP-1 medications

In a 2-year trial, acute pancreatitis was confirmed by adjudication in 8 OZEMPIC-treated patients (0.27 cases per 100 patient years) and 10 placebo-treated patients (0.33 cases per 100 patient years), both on a background of standard of care

For those considering semaglutide, the CMP can reveal underlying issues that might impact treatment safety and effectiveness

Results Require Lifestyle Changes It is very important to note that semaglutide is not a magic bullet